Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis
MIs significantly improve symptomatic, functional, and biomarker outcomes in symptomatic HCM while maintaining an acceptable safety profile, highlighting their potential as a transformative treatment option. Further studies are warranted to evaluate long-term efficacy and safety.
Authors
- Jawad Basit (ORCID: https://orcid.org/0000-0002-5298-019X)
- Jared Kvapil
- Mohammad Hazique (ORCID: https://orcid.org/0009-0002-9870-6951)
- Abdul Rasheed Bahar (ORCID: https://orcid.org/0000-0003-2940-6074)
- Sunam Kafle
- Sameer Lohana
- Kunal N. Patel (ORCID: https://orcid.org/0000-0003-2712-0670)
- M Chadi Alraies
- Jasgit Bhinder
Institutions
- Rawalpindi Medical University (PK)
- Wayne State University (US)
- Detroit Medical Center (US)
- University of Kansas Medical Center (US)
- Vassar Brothers Medical Center (US)
Publication Details
- Journal
- Archives of Medical Science - Atherosclerotic Diseases
- Published
- 2025-10-03
- DOI
- https://doi.org/10.5114/amsad/209038
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00